Diadema Partners LP Acquires Shares of 300,000 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Diadema Partners LP bought a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 300,000 shares of the company's stock, valued at approximately $6,677,000. Teva Pharmaceutical Industries comprises about 2.8% of Diadema Partners LP's holdings, making the stock its 5th biggest position.

Several other institutional investors also recently added to or reduced their stakes in the business. Diversify Advisory Services LLC lifted its stake in shares of Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock valued at $426,000 after buying an additional 496 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 1.9% in the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after acquiring an additional 664 shares during the period. Thrivent Financial for Lutherans grew its holdings in shares of Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after purchasing an additional 699 shares in the last quarter. Townsquare Capital LLC grew its holdings in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after purchasing an additional 812 shares in the last quarter. Finally, Metis Global Partners LLC increased its position in shares of Teva Pharmaceutical Industries by 6.7% during the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after purchasing an additional 860 shares during the period. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded up $0.16 on Friday, hitting $14.88. The company's stock had a trading volume of 6,566,648 shares, compared to its average volume of 9,929,030. The company has a market capitalization of $16.87 billion, a PE ratio of -10.26, a PEG ratio of 1.44 and a beta of 0.72. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The company has a 50 day moving average price of $15.23 and a 200 day moving average price of $17.56. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on TEVA shares. Piper Sandler raised their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Barclays decreased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. Finally, Bank of America dropped their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.